PPARγ agonist 2 is a highly effective compound that acts as a partial agonist for PPARγ. It exhibits significant potential for utilization in metabolic disease research [1].
TRβ agonist 2 (Compound 1) is a highly potent agonist of TRβ. Moreover, it effectively reduces lipid accumulation in HepG2 cells and promotes lipolysis, offering comparable effects. With its promising attributes, TRβ agonist 2 emerges as a potential thyromimetics that selectively targets TRβ [1].
5-HT2A receptor agonist-2 is a potent compound that acts as an agonist on the serotonin 5-HT2 receptor. It specifically stimulates the 5-HT 2A, 5-HT 2B, and 5-HT 2C receptors, with EC 50 values of 1.7 nM, 0.58 nM, and 0.50 nM, respectively [1].
Glucocorticoid receptor agonist 2 is a highly effective anti-inflammatory compound, derived from arylpyrazole, that actively binds to and activates the glucocorticoid receptor. This compound exhibits potent anti-inflammatory properties without disrupting insulin secretion.
AhR agonist 2 (Compound 12a) is a highly potent agonist of the aryl hydrocarbon receptor (AhR), exhibiting an EC50 value of 0.03 nM. This compound rapidly induces nuclear enrichment of AhR and initiates transcription of downstream genes, thereby promoting skin barrier repair. AhR agonist 2 shows promising potential for psoriasis research [1].
5-HT7 agonist 2 is a highly potent 5-HT7 receptor agonist, exhibiting an IC50 value of 28.7 nM. This compound holds promise for studying and understanding various Central Nervous System (CNS) disorders [1].